<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03483246</url>
  </required_header>
  <id_info>
    <org_study_id>P 160931J</org_study_id>
    <secondary_id>2017-003802-42</secondary_id>
    <nct_id>NCT03483246</nct_id>
  </id_info>
  <brief_title>Impact of Fecal Microbiota Transplantation in Ulcerative Colitis</brief_title>
  <acronym>REBALANCE-UC</acronym>
  <official_title>Impact of Fecal Microbiota Transplantation in Ulcerative Colitis: a Randomized, Sham Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CRB-HUEP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease. UC pathogenesis
      remains poorly understood but involves an inappropriate immune response toward an unbalanced
      gut microbiota (called dysbiosis) in predisposed hosts.

      The purpose of this study is to determine the effect of the fecal microbiota transplantation
      on UC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease affecting
      approximately 90 000 patients in France, mostly at young age, and altering their quality of
      life.

      Conventional Immunosuppressive treatment (ie azathioprine, anti-TNF (tumor necrosis factor ),
      vedolizumab) used in UC are expensive and associated with potentially severe complications
      such as infections and cancers.

      UC pathogenesis remains poorly understood but involves an inappropriate immune response
      toward an unbalanced gut microbiota (called dysbiosis) in predisposed hosts.

      Fecal microbiota transplantation (FMT) is now recommended in guidelines for treating
      recurrent Clostridium difficile infection. Although the pathogenesis involved in UC is
      different, FMT is a potential therapeutic strategy as transferring a healthy microbiota in an
      UC patient could restore the appropriate host-microbiota crosstalk.

      As the gut microbiota is dramatically altered by intestinal inflammation, transferring a
      massive amount of microbial organisms in an inflamed gut with epithelial barrier disruption
      might be a suboptimal strategy and could even have detrimental effects by allowing bacterial
      translocation.

      Thus, it's possible that performing FMT in UC patients who achieved remission after
      conventional treatment might be associated with better clinical outcome than in patients with
      active disease.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steroid-free clinical and endoscopic remission</measure>
    <time_frame>12 weeks after FMT or sham-transplantation</time_frame>
    <description>Steroid-free clinical and endoscopic remission defined as a Mayo Clinic score of 2 or lower and no subscore higher than 1 and mucosal healing defined as an endoscopic subscore of 0 or 1 (Sigmoidoscopy).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Steroid-free clinical remission</measure>
    <time_frame>12 weeks after FMT or sham-transplantation</time_frame>
    <description>Steroid-free clinical remission defined as a Partial Mayo Clinic score of 0 or 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid-free clinical remission</measure>
    <time_frame>24 weeks after FMT or sham-transplantation</time_frame>
    <description>Steroid-free clinical remission defined as a Partial Mayo Clinic score of 0 or 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid-free endoscopic response</measure>
    <time_frame>12 weeks after FMTor sham-transplantation</time_frame>
    <description>Steroid-free endoscopic response defined as a Mayo endoscopy subscore of 1 or less, with a reduction of at least 1 point from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid-free endoscopic remission</measure>
    <time_frame>12 weeks after FMT or sham-transplantation</time_frame>
    <description>Steroid-free endoscopic remission defined as an Endoscopic Mayo Clinic score of 0 or 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota composition and diversity</measure>
    <time_frame>12 and 24 weeks after FMT or sham-transplantation</time_frame>
    <description>Microbiota composition and diversity assessed by 16s sequencing compared to baseline and to donor's microbiota.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of adverse events in each group</measure>
    <time_frame>Through study completion, an evrage of 4 years</time_frame>
    <description>abdominal pain, nausea, vomiting, fever, modified intestinal transit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory biological parameter 1</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory biological parameter 2</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>fecal calprotectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory biological parameter 3</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>platelet number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic lesions</measure>
    <time_frame>12 weeks after FMT or sham-transplantation</time_frame>
    <description>Endoscopic lesions at coloscopy (baseline) and sigmoidoscopy by endoscopic Mayo score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic lesions</measure>
    <time_frame>12 weeks after FMT or sham-transplantation</time_frame>
    <description>Endoscopic lesions at coloscopy (baseline) and sigmoidoscopy by UCEIS score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Group A - fecal microbiota transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving the fecal microbiota transplantation (FMT) in 3 times after inclusion and randomisation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B- Sham-transplantation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receiving the sham-transplantation in 3 times after inclusion and randomisation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation (FMT)</intervention_name>
    <description>The colonoscopy for FMT will be planned as soon as possible and never more than 5 weeks after inclusion visit.
After colon cleansing using 4 liters of Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.
The patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of physio, see donor section for details) or sham transplantation (FMT vehicle) in the cecum.</description>
    <arm_group_label>Group A - fecal microbiota transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham-transplantation Placebo</intervention_name>
    <description>The sham-transplantation will be planned as soon as possible and never more than 5 weeks after inclusion visit.
After colon cleansing using 4 liters of Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.
The patient will then sham transplantation (FMT vehicle) in the cecum.</description>
    <arm_group_label>Group B- Sham-transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria for patients :

          -  Age ≥ 18 years and &lt; 75 years

          -  Ulcerative colitis (according to the Lennard Jones criteria) diagnosed for at least 3
             months and :

               -  Currently active (PMC &gt; 1) and planned to be treated by corticosteroids (minimum
                  40mg daily) Or

               -  Currently treated by high-level systemic corticosteroid (minimum 40 mg prednisone
                  equivalent daily) within max 3 weeks Or

               -  Steroid dependent patients (at least one unsuccessful attempt to discontinue
                  steroid within the last 12 weeks before inclusion)

          -  Patient with health insurance (AME excepted)

          -  Informed written consent

        Inclusion Criteria for donors :

          -  Age ≥ 18 years and &lt; 50 years

          -  17 kg/m² &lt; body mass index &lt; 30 kg/m²

          -  Regular bowel movement in the morning

          -  Subject with health insurance (AME excepted)

          -  Informed Written consent

        Exclusion Criteria:

        Exclusion Criteria for patients :

          -  UC complication requiring surgical treatment

          -  Patient treated with high dose corticosteroid more than three weeks before inclusion
             (≥ 40 mg prednisone equivalent daily) except in case of steroid-dependence

          -  Contraindication to colonoscopy or anesthesia

          -  Pregnancy

          -  Treatment preceding the colonoscopy with:

               -  infliximab and/or vedolizumab (&lt; 6 weeks before the planned date of the
                  colonoscopy) and/or adalimumab (&lt;2 weeks before the planned date of the
                  colonoscopy) and/or golimumab (&lt;4 weeks before the planned date of the
                  colonoscopy)

               -  immunosuppressant (thiopurine, methotrexate, tacrolimus or other classical
                  immunosuppressant) started or stopped &lt; 3 months before the planned date of the
                  colonoscopy

               -  Antibiotics, antifungic or probiotics treatment &lt; 4 weeks before the planned date
                  of the colonoscopy

          -  participation in any other interventional study

        Exclusion Criteria for donors :

        - For details, please see protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry SOKOL, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harry SOKOL, PU-PH</last_name>
    <phone>01 49 28 31 62</phone>
    <email>harry.sokol@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurent BEAUGERIE, PU-PH</last_name>
    <phone>01 49 28 31 62</phone>
    <email>laurent.beaugerie@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Gastroentérologie et Nutrition Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harry SOKOL, PU-PH</last_name>
      <phone>01 49 28 31 62</phone>
      <email>harry.sokol@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015 Apr;12(4):205-17. doi: 10.1038/nrgastro.2015.34. Epub 2015 Mar 3. Review.</citation>
    <PMID>25732745</PMID>
  </reference>
  <reference>
    <citation>Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Papay P, Novacek G, Trauner M, Loy A, Berry D. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol. 2013 Oct;108(10):1620-30. doi: 10.1038/ajg.2013.257. Epub 2013 Sep 24.</citation>
    <PMID>24060759</PMID>
  </reference>
  <reference>
    <citation>Beaugerie L, Itzkowitz SH. Cancers Complicating Inflammatory Bowel Disease. N Engl J Med. 2015 Jul 9;373(2):195. doi: 10.1056/NEJMc1505689.</citation>
    <PMID>26154801</PMID>
  </reference>
  <reference>
    <citation>Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976 Mar;70(3):439-44.</citation>
    <PMID>1248701</PMID>
  </reference>
  <reference>
    <citation>Borody T, Fischer M, Mitchell S, Campbell J. Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead. Expert Rev Gastroenterol Hepatol. 2015;9(11):1379-91. doi: 10.1586/17474124.2015.1086267. Epub 2015 Sep 28. Review.</citation>
    <PMID>26414076</PMID>
  </reference>
  <reference>
    <citation>Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2014 Dec;8(12):1569-81. doi: 10.1016/j.crohns.2014.08.006. Epub 2014 Sep 13. Review.</citation>
    <PMID>25223604</PMID>
  </reference>
  <reference>
    <citation>Cui B, Li P, Xu L, Zhao Y, Wang H, Peng Z, Xu H, Xiang J, He Z, Zhang T, Nie Y, Wu K, Fan D, Ji G, Zhang F. Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis. J Transl Med. 2015 Sep 12;13:298. doi: 10.1186/s12967-015-0646-2.</citation>
    <PMID>26363929</PMID>
  </reference>
  <reference>
    <citation>D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb;132(2):763-86. Epub 2006 Dec 20. Review.</citation>
    <PMID>17258735</PMID>
  </reference>
  <reference>
    <citation>Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014 Mar;20 Suppl 2:1-26. doi: 10.1111/1469-0691.12418.</citation>
    <PMID>24118601</PMID>
  </reference>
  <reference>
    <citation>Grinspan AM, Kelly CR. Fecal Microbiota Transplantation for Ulcerative Colitis: Not Just Yet. Gastroenterology. 2015 Jul;149(1):15-8. doi: 10.1053/j.gastro.2015.05.030. Epub 2015 May 27.</citation>
    <PMID>26021232</PMID>
  </reference>
  <reference>
    <citation>Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, Aroniadis O, Barto A, Borody T, Giovanelli A, Gordon S, Gluck M, Hohmann EL, Kao D, Kao JY, McQuillen DP, Mellow M, Rank KM, Rao K, Ray A, Schwartz MA, Singh N, Stollman N, Suskind DL, Vindigni SM, Youngster I, Brandt L. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014 Jul;109(7):1065-71. doi: 10.1038/ajg.2014.133. Epub 2014 Jun 3.</citation>
    <PMID>24890442</PMID>
  </reference>
  <reference>
    <citation>Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, Moore T, Wu G. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology. 2015 Jul;149(1):223-37. doi: 10.1053/j.gastro.2015.05.008. Epub 2015 May 15. Review.</citation>
    <PMID>25982290</PMID>
  </reference>
  <reference>
    <citation>Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011 Jun 15;474(7351):307-17. doi: 10.1038/nature10209. Review.</citation>
    <PMID>21677747</PMID>
  </reference>
  <reference>
    <citation>Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, Bridonneau C, Jegou S, Hoffmann TW, Natividad JM, Brot L, Taleb S, Couturier-Maillard A, Nion-Larmurier I, Merabtene F, Seksik P, Bourrier A, Cosnes J, Ryffel B, Beaugerie L, Launay JM, Langella P, Xavier RJ, Sokol H. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. 2016 Jun;22(6):598-605. doi: 10.1038/nm.4102. Epub 2016 May 9.</citation>
    <PMID>27158904</PMID>
  </reference>
  <reference>
    <citation>Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jørgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clément K, Doré J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T; MetaHIT consortium, Bork P, Wang J, Ehrlich SD, Pedersen O. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013 Aug 29;500(7464):541-6. doi: 10.1038/nature12506.</citation>
    <PMID>23985870</PMID>
  </reference>
  <reference>
    <citation>Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, Weese JS, Collins S, Moayyedi P, Crowther M, Ropeleski MJ, Jayaratne P, Higgins D, Li Y, Rau NV, Kim PT. Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA. 2016 Jan 12;315(2):142-9. doi: 10.1001/jama.2015.18098.</citation>
    <PMID>26757463</PMID>
  </reference>
  <reference>
    <citation>Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6; discussion 16-9.</citation>
    <PMID>2617184</PMID>
  </reference>
  <reference>
    <citation>Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012 Oct;9(10):599-608. doi: 10.1038/nrgastro.2012.152. Epub 2012 Aug 21. Review.</citation>
    <PMID>22907164</PMID>
  </reference>
  <reference>
    <citation>Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W, Lee CH. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology. 2015 Jul;149(1):102-109.e6. doi: 10.1053/j.gastro.2015.04.001. Epub 2015 Apr 7.</citation>
    <PMID>25857665</PMID>
  </reference>
  <reference>
    <citation>Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflou A, Löwenberg M, van den Brink GR, Mathus-Vliegen EM, de Vos WM, Zoetendal EG, D'Haens GR, Ponsioen CY. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology. 2015 Jul;149(1):110-118.e4. doi: 10.1053/j.gastro.2015.03.045. Epub 2015 Mar 30.</citation>
    <PMID>25836986</PMID>
  </reference>
  <reference>
    <citation>Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, Cohen D, Liguori G, Bourrier A, Nion-Larmurier I, Cosnes J, Seksik P, Langella P, Skurnik D, Richard ML, Beaugerie L. Fungal microbiota dysbiosis in IBD. Gut. 2017 Jun;66(6):1039-1048. doi: 10.1136/gutjnl-2015-310746. Epub 2016 Feb 3.</citation>
    <PMID>26843508</PMID>
  </reference>
  <reference>
    <citation>Sokol H, Galperine T, Kapel N, Bourlioux P, Seksik P, Barbut F, Scanzi J, Chast F, Batista R, Joly F, Joly AC, Collignon A, Guery B, Beaugerie L; French Group of Faecal microbiota Transplantation (FGFT). Faecal microbiota transplantation in recurrent Clostridium difficile infection: Recommendations from the French Group of Faecal microbiota Transplantation. Dig Liver Dis. 2016 Mar;48(3):242-7. doi: 10.1016/j.dld.2015.08.017. Epub 2015 Sep 7.</citation>
    <PMID>26433619</PMID>
  </reference>
  <reference>
    <citation>Sokol H. Toward Rational Donor Selection in Faecal Microbiota Transplantation for IBD. J Crohns Colitis. 2016 Apr;10(4):375-6. doi: 10.1093/ecco-jcc/jjw005. Epub 2016 Jan 7.</citation>
    <PMID>26746170</PMID>
  </reference>
  <reference>
    <citation>Suskind DL, Singh N, Nielson H, Wahbeh G. Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2015 Jan;60(1):27-9. doi: 10.1097/MPG.0000000000000544.</citation>
    <PMID>25162366</PMID>
  </reference>
  <reference>
    <citation>Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008 Apr;134(4):929-36. doi: 10.1053/j.gastro.2008.01.012. Epub 2008 Jan 11.</citation>
    <PMID>18294633</PMID>
  </reference>
  <reference>
    <citation>van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013 Jan 31;368(5):407-15. doi: 10.1056/NEJMoa1205037. Epub 2013 Jan 16.</citation>
    <PMID>23323867</PMID>
  </reference>
  <reference>
    <citation>Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, Ferrante M, Van Assche G, Rutgeerts P, Raes J. Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. J Crohns Colitis. 2016 Apr;10(4):387-94. doi: 10.1093/ecco-jcc/jjv203. Epub 2015 Oct 29.</citation>
    <PMID>26519463</PMID>
  </reference>
  <reference>
    <citation>Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012 Oct;143(4):913-6.e7. doi: 10.1053/j.gastro.2012.06.031. Epub 2012 Jun 20. Erratum in: Gastroenterology. 2013 Jan;144(1):250.</citation>
    <PMID>22728514</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2018</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative colitis</keyword>
  <keyword>Inflammatory bowel disease</keyword>
  <keyword>Fecal microbiota transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

